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O B J E C T I V E S This study sought to analyze the effectiveness of cardiac resynchronization therapy
(CRT) related to the viability in the segment of left ventricular (LV) lead position deﬁned by myocardial
deformation imaging.
B A C KG ROUND Echocardiographic myocardial deformation analysis allows determination of LV
lead position as well as extent of myocardial viability.
METHOD S Myocardial deformation imaging based on tracking of acoustic markers within
2-dimensional echo images (GE Ultrasound, GE Healthcare, Horton, Norway) was performed in 65
heart failure patients (54  6 years of age, 41 men) before and 12 months after CRT implantation.
In a 16-segment model, the LV lead position was deﬁned based on the segmental strain curve with
earliest peak strain, whereas the CRT system was programmed to pure LV pacing. Nonviability of a
segment (transmural scar formation) was assumed if the peak systolic circumferential strain was
–11.1%.
R E S U L T S In 47 patients, the LV lead was placed in a viable segment, and in 18 patients, it was
placed in a nonviable segment. At 12-month follow-up there was greater decrease of LV end-diastolic
volumes (58  13 ml vs. 44  12 ml, p  0.0388) and greater increase of LV ejection fraction (11  4%
vs. 5  4%, p  0.0343) and peak oxygen consumption (2.5  0.9 ml/kg/min vs. 1.7  1.1 ml/kg/min,
p 0.0465) in the viable compared with the nonviable group. The change in LV ejection fraction and
the reduction in LV end-diastolic volumes at follow-up correlated to an increasing peak systolic
circumferential strain in the segment of the LV pacing lead (r  0.61, p  0.0274 and r  0.64, p
 0.0412, respectively). Considering only patients with ischemic heart disease, differences between
viable and nonviable LV lead position group were even greater.
CONC L U S I O N S Preserved viability in the segment of the CRT LV lead position results in greater
LV reverse remodeling and functional beneﬁt at 12-month follow-up. Deformation imaging allows
analysis of viability in the LV lead segment. (J Am Coll Cardiol Img 2011;4:366–74) © 2011 by the
American College of Cardiology Foundation
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367ardiac resynchronization therapy (CRT) is
used for the treatment of advanced drug-
refractory heart failure of ischemic and
nonischemic origin (1–5). However, up to
ne-third of patients do not respond to CRT using
tandard clinical selection criteria (5,6). Factors
nfluencing the patient’s response to CRT are not
ompletely understood. Echocardiographic param-
ters suggested to evaluate mechanical dyssyn-
hrony and predict CRT success have not been
See page 375
confirmed in a large multicenter study (7–9). Tech-
nical and procedural factors such as optimal left
ventricular (LV) lead placement seem to have an
important impact. Butter et al. (10) demonstrated
in an experimental analysis that the LV lead should
be placed in the area of greatest delay in mechanical
contraction and electrical activation to achieve the
optimal resynchronization effect. Clinical studies
confirmed that concurrence of the LV lead position
and the LV segment with latest contraction before
CRT results in significantly better effectiveness of
CRT on LV function and clinical outcome (11,12).
Ischemic etiology of heart failure has been identi-
fied as a predictor of impaired responsiveness (13).
The extent of scar tissue has been shown to define
the response to CRT (14–17). The response to
CRT may thus be directly related to the extent of
myocardial viability in the area of the LV lead and
nonresponse in ischemic heart failure may be the
consequence of the LV lead being positioned in a
scarred segment without functional capacity.
Myocardial deformation imaging can be used to
define CRT LV lead position and determine myo-
cardial viability. Temporal analysis of segmental
myocardial deformation curves has been shown to
allow definition of LV lead position (11,18). The
magnitude of peak segmental myocardial strain
closely relates to segmental viability (19,20).
This study sought to determine CRT effective-
ness related to the viability of the segment with the
LV lead position as well as the area surrounding the
LV lead segment. Viability was defined by analysis
of myocardial deformation.
M E T H O D S
Patients. We included in this study 65 consecutive
atients (mean age 55  4 years, 39 men) with
nd-stage heart failure severe LV systolic dysfunc-
ion (ejection fraction [EF] 35%), scheduled for mew implantation of a biventricular pacemaker.
atients had to be in New York Heart Association
unctional class III (n  48) or IV (n  17) despite
ptimal pharmacologic therapy and show sinus
hythm with a QRS interval duration 120 ms.
tiology of heart failure was ischemic in 46 patients
nd nonischemic in 19 patients based on coronary
ngiography. No studies to assess myocardial viability
ere performed before CRT implantation. This study
as approved by the local ethical committee and all
ubjects gave written informed consent.
Biventricular device implantation. The LV pacing
ead was inserted by a transvenous approach
hrough the coronary sinus into a cardiac vein of the
ree wall. An average of 2.1 veins were tried
ntraoperatively to achieve an optimal LV lead
osition. Optimal LV lead position was considered to
e when the width of the QRS complex was mini-
ized and the arterial systolic pressure increased. No
nformation about presence of myocardial viability or
rea of latest activation was provided intra-
peratively. The right atrial and ventricu-
ar leads were positioned conventionally.
ll patients received a biventricular
ardioverter-defibrillator (Attain-System
ith InSync Marquis, Medtronic, Minne-
polis, Minnesota [n  40] or Aesula-
ystem with Epic HF V-339, St. Jude
edical, St. Paul, Minnesota [n  25]).
Post-operatively the optimal atrioven-
ricular time was determined by Doppler
chocardiography and set between 100
nd 150 ms (mean time 122  10 ms) in
1 patients and between 70 and 85 ms
mean time 75  8 ms) in 4 patients. The
entriculo-ventricular time was set to 0 in all
atients. Thresholds for sensing and pacing of the
V lead at the final position were documented.
To exclude LV lead dislocation and change of
V time, the device was controlled at 6- and
2-month follow-up. Seven days after implantation
f the CRT system, transient programming of the
evice to pure LV pacing was performed during an
chocardiographic examination to determine the
V lead position.
Echocardiography. All studies were performed be-
ore CRT, one day after implantation, and at 12 (
)-month follow-up using a Vivid Seven digital
ltrasound scanner (General Electric, Horton, Nor-
ay). Using apical 4- and 2-chamber views, LVEF
nd left ventricular end-diastolic volume (LVEDV)
ere determined employing biplane Simpson
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368graphic analyses was blinded to the physician per-
forming the LV lead placement.
Analysis of myocardial deformation. For analysis of
V myocardial deformation, the 16-segment model
as applied on 3 parasternal short-axis views: 6
egments each on the basal and on the papillary
uscle levels and 4 segments on the apical level.
he frame rate was between 56 and 92 frames/s, the
ocus was adjusted to the center of the LV cavity for
ptimized characterization of myocardial tissue.
sing 2 consecutive cardiac cycles, myocardial de-
ormation analysis was performed offline with the
id of a customized software package (EchoPAC
T 05.2, General Electric). This software follows
coustic markers within the myocardium during
everal consecutive frames (21) and calculates mean
train values for whole pre-defined LV segments
22). It is assumed that these natural acoustic
arkers change their position from frame to frame
n accordance with the surrounding tissue motion.
isual control of width between endocardial and
ericardial trace as well as tracking quality was
erformed to ensure accurate analysis. End-systole
as determined in the apical long-axis view as
ortic valve closure. The time difference from the
RS complex was transferred to the other views.
he focus was adjusted to the center of the LV
avity to optimize myocardial speckle characteristics
f all segments.
Circumferential strain relates to circumferential
eformation along the LV curvature. It is calculated
s mean over the whole segment. Myocardial de-
ormation analysis was used to define the LV lead
osition. The LV lead position was defined as the
egment with the earliest peak on the segmental
train curve analysis, whereas the CRT system was
rogrammed to pure LV pacing (18).
Viability of LV segments was determined based
n the segmental peak systolic circumferential
train before CRT implantation. This information
as not provided to the physician performing the
mplantation procedure. A peak systolic circumfer-
ntial strain –11.1% was considered to indicate
yocardial viability (no scar or nontransmural scar),
hereas a peak systolic circumferential strain
–11.1% was considered to indicate nonviability
transmural scar formation) as shown before (19)
Fig. 1). In addition, viability of the adjacent
egments of the LV lead position segment was
valuated. This assessment was based on application
f a 16-segment LV model. There were 4 adjacent
egments in case of midventricular LV lead position
nd 3 adjacent segments in case of basal or apical sV lead position. Viability of the surrounding area
f the LV lead segment was defined as viability in at
east 3 adjacent segments in case of midventricular
V lead position, and as viability in at least 2
djacent segments in case of basal or apical LV lead
osition.
Peak oxygen consumption. Patients underwent bicy-
le cardiopulmonary exercise testing (10 W per min
ncrements) at baseline and after 12 (3) months of
RT. The peak oxygen consumption (VO2max) at
peak exercise was defined as the highest oxygen
consumption measured during the symptom-
limited exercise test and expressed as ml/kg/min.
Statistics. Continuous data are expressed as mean
 SD and have been compared using Student t
est or analysis of variance as appropriate. Pearson
orrelation coefficient was determined and linear
egression analysis was performed to define the
elationship between parameters with continuous
ata. Categorical data are presented as frequen-
ies and were compared with Pearson chi-square
est. The receiver-operator characteristics (ROC)
urve for peak circumferential systolic strain in
he segment of the LV pacing lead was examined
o define the optimal cutoff for prediction of
RT response. The area under ROC curve was
alculated. A p value of 0.05 was considered
Figure 1. CS Tracings Related to CRT Response
(A) Circumferential strain (CS) tracings during left ventricular (LV)
pacing. The anterior segment at the mid-ventricular level
showed earliest peak strain among all 16 segments and was
deﬁned as LV lead position. The segment was deﬁned as nonvi-
able, as the peak CS was –9.8% and, therefore, less than the via-
bility cutoff value of –11.1%. This patient was a nonresponder
to cardiac resynchronization therapy (CRT) (increase of left ven-
tricular ejection fraction [LVEF] 2% and reduction of left ventric-
ular end-diastolic volume [LVEDV] 18 ml). (B) The lateral
segment at the mid-ventricular level was deﬁned as LV lead
position and as viable (peak CS  –17.2%). This patient was a
responder to CRT (increase of LVEF 8% and reduction of LVEDV
44 ml).tatistically significant.
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369R E S U L T S
Baseline characteristics. Clinical baseline character-
istics of all patients related to viability in the
segment of the LV pacing lead are given in Table 1.
There were no significant differences in patient
characteristics as well as medication. Myocardial
deformation analysis could be performed in 946 of
1,040 segments. Based on analysis of segmental
peak circumferential strain, 683 segments were
found to be viable and 263 segments were found to
be nonviable.
LV lead position. The LV lead position was defined
considering the segment with earliest peak strain
during pure LV pacing as follows: 18 anterior (10
basal, 8 medial), 29 lateral (17 basal, 9 medial, 3
apical), 12 posterior (5 basal, 7 medial), and 6
inferior (4 basal, 2 apical).
Impact ofmyocardial viability at LV lead position. Forty-
even patients were found to have preserved viabil-
ty at the LV pacing lead segment and 18 patients
ad not. Within these segments, mean peak systolic
ircumferential strain was –14.8  2.9% and –8.3 
.6%, respectively. Sensing thresholds were 19  6
V and 13  4 mV for LV leads positioned in
iable and nonviable segments, respectively (p 
.042). Pacing thresholds were 1.6 0.4 V and 2.4 
.5 V for LV leads positioned in viable and nonvi-
ble segments, respectively (p  0.059). Compari-
son of baseline results and results obtained at 12
months after CRT implantation demonstrated a
greater increase in LVEF (LVEF 11  4% vs. 5
 4%, p  0.0343), reverse remodeling (LVEDV
8  13 ml vs. 44  12 ml, p  0.0388), and peak
xygen consumption (VO2max 2.5  0.9 ml/kg/
in vs. 1.7  1.1 ml/kg/min, p  0.0465) for
atients with the LV pacing lead placed in a viable
egment compared with the nonviable group (Table
).
The change in LVEF and the reduction in
VEDV at 12-month follow-up correlated to an
ncreasing peak systolic circumferential strain in the
egment of the LV pacing lead (r  0.61, p 
.0274 and r 0.64, p 0.0412, respectively) (Fig. 2).
atients with an improvement in LVEF of 5%
ere classified as responders. Referring to this
efinition, 5 (of 47) patients in the viable and 15 (of
8) patients in the nonviable LV pacing lead region
ere nonresponders to CRT.
The ROC analysis for prediction of CRT re-
ponse considering the peak systolic circumferential
train in the segment of the LV pacing lead dem-
nstrated a cutoff value of –11.9%. The area underhe curve was 0.757 (95% confidence interval: 0.693
o 0.818). Considering this cutoff value for peak
ystolic circumferential strain, sensitivity and spec-
ficity to predict CRT response were 73% and 77%,
espectively.
There was an incremental increase in EF as
ell as decrease in LVEDV dependent on viabil-
ty of the LV lead segments as well as viability of
he surrounding area. Whereas changes in EF
nd LVEDV were lowest if the LV lead segment
s well as the surrounding area were nonviable,
hanges in EF and LVEDV were greatest if the
V lead segment as well as the surrounding area
ere viable (Fig. 3). Considering viability of the
otal LV, there was a correlation between amount
f total LV viability and change in EF as well as
VEDV at follow-up. The greater the amount of
iability of the LV was, the greater was found to
e the increase in EF as well as the decrease in
VEDV (Fig. 4).
Impact of viability in patients with ischemic cardiomy-
opathy. Considering only the 46 patients with
schemic cardiomyopathy, there were 32 patients
ith the LV lead being placed in a viable segment
nd 14 patients with the LV lead being placed in
nonviable segment. The difference between
atients with the LV lead being placed in a viable
r a nonviable segment was more pronounced
han when considering all patients (Table 3).
onsidering the 46 patients with ischemic car-
Table 1. Patient Characteristics at Baseline Before CRT Related
in the LV Lead Segment
LV Lead Segment
Viable (n  47) Nonviable (n
Age, yrs 54 5 53 7
Men 28 (59%) 11 (61%)
Ischemic cardiomyopathy 33 (71%) 13 (74%)
QRS duration, ms 160 9 159 10
NYHA functional classiﬁcation 3.2 0.5 3.2 0.
LVEDV, ml 311 81 306 86
VO2max, ml/kg/min 13.7 1.5 13.5 1.
LVEF, % 31 4 30 6
Concomitant therapy
ACE inhibitors 37 (78%) 13 (74%)
ARBs 9 (19%) 3 (16%)
Beta-blockers 42 (90%) 16 (88%)
Digitalis 15 (31%) 6 (34%)
Diuretics 21 (45%) 8 (46%)
Aldosterone antagonists 30 (64%) 11 (61%)
The LV lead position was deﬁned with myocardial deformation imaging during
ACE  angiotensin-converting enzyme; ARB  angiotensin II receptor bl
ventricular end-diastolic volume; LVEF  left ventricular ejection fraction; NYHto Viability
 18) p Value
0.642
0.478
0.297
0.329
7 0.451
0.352
6 0.628
0.337
0.427
0.683
0.559
0.673
0.548
0.281
pure LV pacing.
ockers; LVEDV left
A  New York HeartAssociation; VO2max  peak oxygen consumption.
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370diomyopathy, the distribution was as follows: 33
patients were classified as responder (3 of 14
patients in the nonviable group and 30 of 32
patients in the viable group), and 13 patients were
Table 2. LVEF, LVEDV, and VO2max Before CRT and
at 12-Month Follow-Up for Patients With Viable or
Nonviable LV Lead Segment
LV Lead Position
Determined During
Pure LV Pacing
LVEF, %
Viable segment of LV lead position
Baseline LVEF 31 5
Follow-up LVEF 42 6
∆LVEF 11 4
Nonviable segment of LV lead position
Baseline LVEF 30 7
Follow-up LVEF 35 6
∆LVEF 5 4
Difference in ∆LVEF
(viable – nonviable group) 6.0
(95% CI) (2.5–7.9)
p value for ∆LVEF
(viable vs. nonviable group)
0.0343
LVEDV, ml
Viable segment of LV lead position
Baseline LVEDV 321 54
Follow-up LVEDV 263 62
∆LVEDV 58 13
Nonviable segment of LV lead position
Baseline LVEDV 316 59
Follow-up LVEDV 272 60
∆LVEDV 44 12
Difference in ∆LVEDV
(viable – nonviable group) 14.0
(95% CI) (8.6–16.3)
p value for ∆LVEDV
(viable vs. nonviable group)
0.0388
VO2max, ml/kg/min
Viable segment of LV lead position
Baseline VO2max 13.4 1.3
Follow-up VO2max 15.9 1.6
∆ VO2max 2.5 0.8
Nonviable segment of LV lead position
Baseline VO2max 13.4 1.3
Follow-up VO2max 15.1 1.5
∆ VO2max 1.7 1.1
Difference in ∆ VO2max, ml/kg/min
(viable – nonviable group) 1.0
(95% CI) (0.4–1.8)
p value for ∆VO2max
(viable vs. nonviable group)
0.0465
The LV lead position was deﬁned with myocardial deformation imaging
during pure LV pacing.
CI  conﬁdence interval; other abbreviations as in Table 1.classified as nonresponders. In nonischemic car-diomyopathy, the difference in LVEF and
LVEDV at follow-up between patients with the
V lead being placed in a segment with circum-
erential strain –11.1% or –11.1% tended to be
ess (LVEF  5.0% and LVEDV  11.4%).
D I S C U S S I O N
The major findings of this study are the following:
1) preserved viability in the segment of the LV lead
position results in greater LV reverse remodeling
and functional benefit at 12-month follow-up;
2) there is incremental CRT effectiveness with
preserved viability of the LV pacing lead segment as
well as the surround segments; and 3) considering
only patients with ischemic cardiomyopathy, the
influence of viability of the LV lead segment is
pronounced.
Optimal LV lead position in CRT. Several studies have
emonstrated that a significant rate of patients do
ot respond positively to CRT using standard
election criteria (1–3). Technical factors such as an
ptimal LV pacing site have been identified as
mportant parameters to determine the success of
Figure 2. Change in LV Function Related to CS at Baseline
(A) Increase in LVEF from baseline to 12-month follow-up
related to peak systolic CS in the segment of the LV pacing
lead. The LV lead segment was deﬁned as the segment with
earliest peak systolic CS during pure LV pacing. (B) Reduction in
LVEDV from baseline to 12-month follow-up related to peak sys-
tolic CS in the segment of the LV pacing lead. Abbreviations as
in Figure 1.
.05.
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371CRT. Experimental data suggested placing the LV
lead in the area of the latest contraction before
CRT (10). Clinical studies confirmed the impor-
Figure 3. Change in LV Function and Volumes Related to Viabil
Increase in LVEF and reduction in LVEDV related to viability (: via
(LS) and viability of surrounding segments (SS). #p  0.001; *p  0
Figure 4. LV Viability and Follow-Up Change in LV Function
and Volumes
Correlation between percentage of viable segments determined by
myocardial deformation analysis (peak systolic circumferential strain
–11.1%) and effectiveness of CRT deﬁned as increase in LVEF (A)
and reduction in LVEDV (B). Abbreviations as in Figure 1.tance of optimal LV lead placement site, demon-
strating improved exercise tolerance, greater im-
provement in LV function, and better outcome for
patients with concordance of LV lead position to
site of latest contraction before CRT (11,12). Dif-
ferent imaging techniques have been used to define
the LV lead site. Fluoroscopy has been used in a
large study demonstrating differences in patient
outcome depending on the LV lead site defined by
fluoroscopy (12). However, because of the limited
fluoroscopic views applied in clinical studies, the
segmental definition of the lead position is con-
,: no viability) of LV segment with assumed LV lead position
Abbreviations as in Figure 1.
Table 3. Comparison of Baseline to 12-Month Follow-Up
Results (LVEF, LVEDV, and VO2max) Considering Only
Patients With Ischemic Cardiomyopathy (n  46)
LV Lead Position
Determined During
Pure LV Pacing
Difference in ∆LVEF, %
(viable – nonviable group) 7.0
(95% CI) (3.7–9.8)
p value for ∆LVEF (viable vs. nonviable) 0.001
Difference in ∆LVEDV, ml
(viable – nonviable group) 16.0
(95% CI) (11.3–19.7)
p value for ∆LVEDV (viable vs. nonviable) 0.001
Difference in ∆VO2max, ml/kg/min
(viable – nonviable group) 1.4
(95% CI) (0.6–2.6)
p value for ∆VO2max (viable vs. nonviable) 0.001ity
bilityAbbreviations as in Tables 1 and 2.
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372fined. Techniques based on myocardial deforma-
ion imaging have been shown to allow improved
efinition of LV lead position (11,18). In this
tudy, we used a technique that defines the LV
ead position as the segment with earliest me-
hanical activity during pure LV pacing. It has
een demonstrated to provide facilitated access to
he LV pacing site (18).
Impact of viability on response to CRT. It has also
een suggested that the extent of scar tissue as
ell as the extent of viable myocardium are
mportant factors defining the response to CRT
14 –17). Bleeker et al. (23) suggested that pacing
he LV in nonviable or scared myocardium results
n a less optimal response to CRT. Some studies
ave found global extent of LV scar to be
mportant (15,16), whereas other studies found
he size of septal or lateral scar significant (17). A
tudy by Ypenburg et al. (17) demonstrated a
irect association between viability determined by
ated single-photon emission computed tomog-
aphy and response to CRT. The increase in LV
unction and the decrease of LV end-systolic and
nd-diastolic volumes at 6-month follow-up were
inearly related to the extent of viability. Addi-
ionally, the extent of scar tissue was also impor-
ant for the response to CRT as reflected by an
nverse relation between the scar tissue and the
hange in LV function and LV volumes.
In an echocardiographic study, transmural scar
as diagnosed based on measurement of an end-
iastolic wall thickness 0.5 cm associated with
ncreased tissue acoustic reflectance (24). The echo-
ardiographic extent of scar tissue was significantly
ssociated with LV reverse remodeling. The greater
he pre-implant myocardial scar tissue, the lower
he reverse remodeling effect of CRT. This is in line
ith results by Mangiavacchi et al. (25), who
eported that the number of scar segments evalu-
ted by echocardiography was less in CRT respond-
rs than in nonresponders. However, these studies
id not specifically focus on myocardial viability of
he LV pacing segment.
In the present study, a peak systolic circumfer-
ntial strain of –11.1% was used to define seg-
ental myocardial viability. This value was deter-
ined in a recent study and had a sensitivity of 70%
nd a specificity of 71% to detect transmural myo-
ardial infarction defined by magnetic resonance
maging (19). In this study, we evaluated LV
olumes and functional capacity at baseline and at
2 months after CRT implantation related to via-
ility of the LV lead segment. A greater increase inVEF, reverse remodeling, and peak oxygen con-
umption could be demonstrated for patients with
iability at the LV pacing lead position versus
atients in the nonviable group. Furthermore, the
mprovement in LVEF and the reduction in
VEDV correlated to an increasing peak systolic
ircumferential strain in the region of LV pacing
ead as a marker of increasing viability. The simi-
arity of the cutoff value found in the ROC analysis
n peak systolic circumferential strain in the seg-
ent with the LV pacing lead for prediction of
RT response to a previously reported cutoff value
or circumferential strain to predict myocardial viabil-
ty (19) stresses the importance of myocardial viability
t the LV lead position for CRT effectiveness.
The results on importance of myocardial viability
or CRT effectiveness are consistent to results by
angiavacchi et al. (25) as well as Chalil et al. (26),
ho reported an association between increasing
xtent and transmurality of scar and poor response
o CRT. Patients with scar transmurality of 52%
howed only one-half symptomatic responder rate
improvement was New York Heart Association
unctional class 1 or 6-min walking distance
25%) observed in patients with a scar transmural-
ty of 51%. Considering the results of these
tudies, there may be a limit of scar size beyond
hich resynchronization becomes ineffective. Sev-
ral factors might contribute to this finding: 1) a
ubstantial amount of viable myocardium is
eeded for improvement in systolic LV function
fter CRT, whereas scar tissue does not contract;
) pacing of scar tissue is likely to result in
uboptimal resynchronization of the neighboring
yocardium as electrical conduction is delayed.
valuation of the extent and location of scar tissue
hould be considered in the selection process for
RT to avoid nonresponse, especially for the area
f latest contraction as optimal segment for the LV
ead placement.
Study limitations. Because there was an insufficient
number of echocardiographic images, myocardial
deformation parameters for analysis of myocar-
dial viability and optimal location for LV lead
could not be determined in 9% of segments.
Thus, the segment with assumed LV lead posi-
tion may have been missed in some patients.
However, this should not have affected the prin-
ciple findings of this study.
The location of the LV lead was determined
based on the assumption that the electric current of
the LV lead will affect the nearest segment stron-
gest and first. This assumption was affirmed before
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373by a high match in the LV lead position determined
by fluoroscopy (11).
There are potential difficulties of speckle tracking
imaging. Circumferential strain values may be im-
paired owing to very tight coronary stenosis
(90%) inducing acute myocardial ischemia (27).
This study focused on analysis of circumferential
strain. This focus considered former analysis dem-
onstrating superiority of circumferential strain to
longitudinal motion analysis in terms of adequate
demonstration of CRT benefit (28).
The analysis approach used in this study may
simplify the complexity of many factors having an
impact on CRT effectiveness. This relates in par-
ticular to technical and procedural factors that are
not all considered. However, myocardial viability,
optimal location of LV lead position, and actual LV
lead position are 3 important factors that influence
CRT effectiveness, and the applied analysis gives
access to all 3 parameters using 1 modality. The
study was not intended to analyze differences be-
tween ischemic and nonischemic cardiomyopathies.
This study found a more pronounced impact of2140–50.
1
1
al. Impact of left vfurther studies should address this issue within
proportionate subgroups. The viability cutoff value
defined for ischemic cardiomyopathy was applied
also to patients with nonischemic cardiomyopathy.
However, as the definition of viability based on
deformation analysis relates to functional capacity,
application of the same cutoff value for nonischemic
cardiomyopathy to predict functional response to
CRT should be a valid approach.
C O N C L U S I O N S
Myocardial deformation imaging provides informa-
tion on LV lead position and myocardial viability.
Preserved viability in the segment of the LV lead
results in greater LV reverse remodeling and func-
tional benefit at 12-month follow-up. The impact
of viability in the LV lead position is particularly
pronounced in patients with ischemic heart disease.
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